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The abundant, liver-specific microRNA miR-122
forms extensive base-pairing interactions with the
50 noncoding region of the hepatitis C virus (HCV)
RNA genome, protecting the viral RNA fromdegrada-
tion. We discovered that the 50-30 exoribonuclease
Xrn2, which plays a crucial role in the transcription
termination of RNA polymerase II, modulates HCV
RNA abundance in the cytoplasm, but is counter-
acted by miR-122-mediated protection. Specifically,
Xrn2 depletion results in increased accumulation
of viral RNA, while Xrn2 overexpression diminishes
viral RNA abundance. Depletion of Xrn2 did not
alter translation or replication rates of HCV RNA,
but affected viral RNA stability. Importantly, during
sequestration of miR-122, Xrn2 depletion restored
HCV RNA abundance, arguing that Xrn2 depletion
eliminates themiR-122 requirement for viral RNA sta-
bility. Thus, Xrn2 has a cytoplasmic, antiviral function
against HCV that is counteracted by HCV’s subver-
sion of miR-122 to form a protective oligomeric com-
plex at the 50 end of the viral genome.
INTRODUCTION
Hepatitis C virus (HCV) is a hepatotropic, positive-sense, envel-
oped RNA virus that belongs to the Flaviviridae. HCV can estab-
lish persistent infections that lead to chronic hepatitis, liver
cirrhosis, and hepatocellular carcinoma (Hoofnagle, 2002). The
HCV 9.6 kb RNA genome contains conserved 50 and 30 noncod-
ing regions (NCRs) that are important for viral replication and
translation. An internal ribosome entry site (IRES) directs the
synthesis of a large, 3,010 amino acid viral polyprotein, which
is co- and posttranslationally cleaved by host and viral proteases
to yieldmature structural and nonstructural proteins (Bartenschl-
ager et al., 2011).
HCV infects an estimated 170 million people worldwide
(Lavanchy, 2011), making it a serious global health problem.
Advances in anti-HCV pharmacology include the recently FDA-
approved NS5B inhibitor sofosbuvir (Gilead Sciences, FosterCell HosCity, CA) and NS3 protease inhibitors simeprevir (Janssen Phar-
maceuticals, Titusville, NJ), telaprevir (Vertex Pharmaceuticals,
Cambridge, MA), and boceprevir (Merck, Whitehouse Station,
NJ). Recently, in phase II clinical trials by Santaris Pharma
(Copenhagen, Denmark), treatment with miravirsen, a modified
oligonucleotide to sequester liver-specific microRNA miR-122
resulted in 1,000-fold-lower HCV titers in HCV patients (Janssen
et al., 2013). Thus, miR-122 is an exciting host cell target to com-
bat HCV. Mechanistically, two miR-122 molecules form an oligo-
meric complex at the 50 proximal end of the HCV RNA genome,
thereby enhancing viral RNA abundance by stabilizing the viral
genome (Jopling et al., 2005, 2008; Li et al., 2013; Machlin et al.,
2011; Shimakami et al., 2012). Here we show that miR-122
protects theHCVRNAgenome fromdegradationby the50-30 exo-
ribonuclease Xrn2, the role of which was thought to be limited to
the transcription termination of RNA polymerase II (Pol II) in the
nucleus (Kim et al., 2004; West et al., 2004). This finding argues
for an unprecedented cytoplasmic antiviral function for Xrn2.
RESULTS
Subcellular Localization and Steady-State Abundance
of Xrn2 during HCV Infection
The 50-30 exoribonuclease Xrn2 executes known nuclear func-
tions in RNA metabolism, including Pol II transcription termina-
tion (Kim et al., 2004; West et al., 2004). However, it was recently
reported that Xrn2 degradesmaturemiRNAs inC. elegans (Chat-
terjee and Grosshans, 2009). To examine whether Xrn2 affects
the turnover of cytoplasmic, mature miR-122 in human cells,
we first monitored the subcellular localization of Xrn2 in unin-
fected and HCV genotype 2a (JFH1)-infected Huh7 cells.
Nuclear and cytoplasmic extracts were prepared, and the distri-
bution of Xrn2, nuclear lamin A/C, and cytoplasmic GAPDHwere
determined by western blot analysis. Figure S1A (available on-
line) shows that Xrn2 is found abundantly in the nucleus, but a
fraction of this protein also resides in the cytoplasm. No changes
in the subcellular distribution of Xrn2 during HCV infection
were observed. To examine more thoroughly the steady-state
abundance of Xrn2 during HCV infection, Xrn2 abundance was
monitored at different times after infection. Western blot analysis
showed that Xrn2 slightly increased during infection, concomi-
tantly with the expression of the HCV NS5A protein (Figure S1B).
This finding suggested the possibility that Xrn2 could either be
facilitating or restricting the HCV replicative cycle.t & Microbe 16, 257–264, August 13, 2014 ª2014 Elsevier Inc. 257
Figure 1. Effects of Xrn2 Depletion on HCV
RNA and Protein Abundance
(A) Effects on RNA abundance. Cells were mock
transfected (Mock), or transfected with control
(NC) or Xrn2 siRNAs. After 1 day, cells were in-
fected with HCV as indicated. RNA abundances
were measured by northern blot analysis 3 days
after infection. The northern blot is representative
of at least three independent replicates (top).
Quantitation of HCV RNA abundance (bottom).
Error bars represent SEM. p value was determined
by Student’s t test.
(B) siRNA-mediated depletion of Xrn2. Abun-
dances of HCV NS5A and core proteins, and
GAPDH were examined. Immunoblot shown is
representative of at least three independent repli-
cates.
(C) Overexpression of Xrn2. 3XFLAG-Xrn2 or
3XFLAG plasmids were transfected 1 day prior to
infection with HCV. HCV and actin RNA abun-
dances were measured by northern blot analysis
3 days after infection. The northern blot shown
represents at least three independent replicates
(top). Quantitation of HCV RNA abundance (bot-
tom). Error bars represent SEM. p value was
determined by Student’s t test.
(D) Effects of Xrn2 depletion on HCV IRES-medi-
ated translation, measured by luciferase assay as
described in the text. The data shown represent
at least three independent replicates. Error bars
represent SEM. p value was determined by Stu-
dent’s t test.
(E and F) Polysomal profile from Xrn2-depleted
cells (top). siRNAs were transfected 1 day prior to
infection. Three days after infection, cell lysates
fromHCV-infected, siXrn2-treated, or siNC-treated
samples were separated in 10%–60% sucrose
gradients. 40S and 60S ribosomal subunits and
polysomes are indicated in the A260nm profile.
Northern blot analyses of the sucrose gradient
fractions (bottom). The northern blots shown
represent at least three independent replicates.
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RNA Abundance
To determinewhether Xrn2 plays a role in theHCV life cycle, Xrn2
was depleted by siRNA-mediated gene knockdown. Depletion
of Xrn2 increased HCV RNA, and HCV NS5A and core protein
abundances (Figures 1A and 1B). Similar effects on viral RNA
and protein abundances were also observed in HCV genotype
1b (5B) replicon cells when Xrn2 was depleted (Figures S1C
and S1D). These findings suggest that enhancement of HCV
RNA and protein abundances during Xrn2 depletion is not
confined to the HCV genotype 2. To exclude off-target effects
of the Xrn2 siRNA, additional siRNAs that target different regions
of the Xrn2 ORF were tested. These siRNAs also enhanced the
abundance of HCV RNA and proteins (Figures S1E and S1F).
In contrast, overexpression of flagged Xrn2 resulted in a 40%258 Cell Host & Microbe 16, 257–264, August 13, 2014 ª2014 Elsevier Inc.decrease in HCV RNA abundance (Fig-
ure 1C), arguing that Xrn2 is antiviral.
We next assessed whether Xrn2 deple-
tion affected the expression of Xrn1, the
other member of the 50-30 exoribonucle-
ase family. Western blot analysis of Xrn1 showed that Xrn2
depletion had no effect on Xrn1 protein abundance (Figure S1G).
Importantly, Figures S1H and S1I show that depletion and over-
expression of Xrn2 have no effect on cell viability or apoptosis.
These results identify a role for cytoplasmic Xrn2 in the regulation
of HCV RNA and protein abundances.
Effects of Xrn2 Depletion on HCV IRES-Mediated
Translation
To identify effects of Xrn2 on HCV IRES-mediated translation,
translation of dicistronic mRNAs, containing the HCV IRES in
the intergenic region, was measured. Specifically, cells were
depleted of Xrn2 by siRNAs on day 1, transfected with dicistronic
plasmids the next day, and first, cistron-encoding Renilla lucif-
erase, and second, cistron-encoding firefly luciferase activities,
Figure 2. Effects of Xrn2 Depletion on HCV RNA Synthesis and
Decay
(A) Effects of Xrn2 depletion on rates of HCV RNA synthesis. siRNAs were
transfected 1 day prior to infection. Abundances of total and newly synthe-
sized HCV and actin RNAs were examined by northern blot analysis 3 days
after infection (top) (Norman and Sarnow, 2010). The northern blot shown is
representative of at least three independent replicates. Replication rates of
HCVRNA correspond to the ratio of newly synthesized HCVRNA to input RNA.
Error bars represent SEM. p values were determined by Student’s t test.
(B) Effects of Xrn2 depletion on HCVRNA decay. Control (siNC) or Xrn2 (siXrn2)
siRNAs were transfected 1 day prior to infection. After 3 days of infection, cells
were treated with 25 mMof the MK-0608 nucleoside analog of HCV NS5B, and
RNAs were extracted at indicated times. HCV RNA levels were measured by
northern blot analysis. Northern blots shown represent at least three inde-
pendent experiments.
(C) One-phase decay graph of HCV RNA. Data from cells harvested at time
0 were set to 1. Data shown represent remaining HCV RNA following addition
of MK-0608. Error bars represent SEM. Estimated half-life (t1/2) of HCV RNA
under these conditions is indicated; ± 95% confidence intervals (CIs) are
0.54–2.24 and 5.82–8.42 in hours for NC and Xrn2, respectively (see Fig-
ure S2). The data shown represent the means of at least three independent
replicates.
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Cell Hoswere measured 24 hr later. Figure 1D shows that HCV IRES-
mediated translation was not affected during Xrn2 knockdown,
indicating that Xrn2 does not modulate HCV IRES activity.
To examine further the apparent lack of effect of Xrn2 on HCV
IRES-mediated translation, polysomal mRNAs were analyzed
from cell lysates obtained from Xrn2-depleted or control siRNA
HCV-infected cells. Sucrose gradient analysis showed that
Xrn2 depletion had little effect on polysomal profile traces (Fig-
ures 1E and 1F), arguing that ribosome density on cellular
mRNAs was not affected during Xrn2 depletion. However, an
increase in abundance of HCV RNA that was associated with
polysomes was observed in Xrn2-depleted extracts (Figure 1F).
To confirm that RNAs associated with polysomal fractions were
indeed translated, lysates were treated with 2mMpuromycin, an
elongation inhibitor that releases ribosomes from mRNAs after
high-salt treatment (Figure S1J). Northern blot analysis of su-
crose gradient fractions showed that actin and viral RNAs from
both control siRNA and Xrn2-depleted samples had decreased
sedimentation upon puromycin treatments (Figure S1J). There-
fore, we conclude that Xrn2 depletion caused the accumulation
of translatable HCV RNA, thus increasing viral protein accumula-
tion. These results point to a role for Xrn2 in decreasingHCVRNA
replication or stability.
Effects of Xrn2 Depletion on Rates of HCV
RNA Replication
To examine whether Xrn2 modulates the rate of HCV RNA syn-
thesis, rates of viral and host cell RNA replication weremeasured
in the presence of or during depletion of Xrn2, using a modified
protocol initially described by Cleary and colleagues (Cleary
et al., 2005). Briefly, control or siRNAs against Xrn2 were trans-
fected into cells 1 day prior to HCV infection. Infected cells
were subsequently incubated with 4-thiouridine (4SU) 3 days
after infection. The modified nucleoside is converted by host
enzymes to 4SU-triphosphate, which is incorporated into newly
synthesized RNA. After extraction, 4SU-labeled RNA was bio-
tinylated and isolated using streptavidin beads (Norman and
Sarnow, 2010). Total and streptavidin-eluted RNAs were then
visualized in northern blots. Figure 2A reveals, as expected, at & Microbe 16, 257–264, August 13, 2014 ª2014 Elsevier Inc. 259
Figure 3. HCV RNA-Xrn2 Interaction and
Protection by miR-122
(A) Xrn2 association with HCV RNA. Representa-
tive northern blot of coimmunoprecipitation re-
actions performed with antibodies against Hif1-a,
Xrn2, and Rck. Lane 1 corresponds to 10%of input
RNA.
(B) Protection of viral RNA by miR-122 from Xrn2-
mediated degradation. 30-32P-labeled capped
(m7G-50), monophosphorylated (p-50), and tri-
phosphorylated (ppp-50) HCV reporter RNAs were
incubated with recombinant human Xrn2 in the
absence (top) or presence of miR-122 (middle) or
miR-124 (bottom) for the indicated periods of time,
and subsequently analyzed by denaturing gel
electrophoresis. Quantitation of radiolabeled RNA
is on the right. Results from at least three inde-
pendent replicates are shown. Error bars represent
SEM. Values were normalized to the 0 min no-Xrn2
control.
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Inspection of streptavidin-eluted RNAs also showed a significant
increase in levels of newly synthesized HCV RNA in Xrn2-
depleted samples. Next, the amount of newly synthesized HCV
RNA was divided by the amount of total HCV RNA, to calculate
the rates of replication. No significant change in viral RNA
replication rates (Figure 2A) during efficient depletion of Xrn2
was observed. This finding argues that Xrn2 depletion enhances
the abundance of HCV RNA without altering the rates of
replication.
Effects of Xrn2 Depletion on HCV RNA Stability
To determine whether Xrn2 affects the decay rate of HCV RNA,
cells were depleted of Xrn2 by siRNAs and subsequently in-
fected with HCV. At 3 days after infection, the nucleoside analog
MK-0608 (Migliaccio et al., 2003) was added to block further viral
RNA synthesis. RNA was extracted at different times after MK-
0608 addition, and HCV RNA abundance was monitored by
northern blot analysis. Viral RNAs from Xrn2-depleted samples
were degraded much more slowly than those from control sam-
ples (Figure 2B). Specifically, HCV RNA was five times more
stable in the absence of Xrn2, displaying a half-life of 6.9 hr as260 Cell Host & Microbe 16, 257–264, August 13, 2014 ª2014 Elsevier Inc.compared to 1.2 hr for siRNA control
samples (Figures 2C and S2). These ob-
servations indicate that Xrn2 decreases
the stability of the viral RNA genome,
likely by its exoribonuclease activity.
HCV RNA-Xrn2 Interaction and HCV
RNA Protection by miR-122
Next, we examined whether Xrn2 asso-
ciates with the viral RNA genome in
JFH1-infected Huh7 cells. RNA coimmu-
noprecipitation experiments were per-
formed using antibodies that recognize
the C terminus of Xrn2; Hif1a andRCK an-
tibodies were used as negative and posi-
tive controls, respectively. Northern blot
analysis of immunoprecipitation reactionsshowed that Xrn2 associates reproducibly with a small fraction of
viral RNA (Figure 3A).
To determine whether HCV RNA is susceptible to the exoribo-
nuclease activity of Xrn2, we tested the activity of recombinant
Xrn2 on various substrate mRNAs containing different 50 end
moieties. The known targets for Xrn2 contain 50 monophos-
phates (Henry et al., 1994; Kim et al., 2004; Morlando et al.,
2004; Qu et al., 1999; Stevens and Poole, 1995; West et al.,
2004). Thus, the 50 triphosphate moiety of the 50 end of HCV (Li
et al., 2013) should be a poor substrate for Xrn2. However, the
original characterization of Xrn2 by Stevens reported that the
protein degrades 50 triphosphate-containing RNA templates as
well (Stevens and Maupin, 1987). When the nuclease activity of
recombinant Xrn2 on 50-monophosphorylated, 50-triphosphory-
lated, and 50-capped HCV domain I-containing RNAs was tested
in in vitro assays (Figure 3B, top), a preference for 50-mono-
phosphorylated RNA was observed. No nuclease activity was
observed for capped RNAs, and modest degradation of 50-tri-
phosphorylated RNA was observed (Figure 3B, top). This finding
argues that full-length HCV RNA may be a direct target for Xrn2.
To assess whether miR-122 functions in protecting the 50 end
of viral RNA from Xrn2 degradation, the susceptibility of modified
Figure 4. HCVRNAAbundance during Sequestration ofmiR-122 and
Depletion of Xrn2
(A) Indicated siRNAs were transfected 1 day prior to infection. miR-122 0.5 nM
or miR-106b LNA 0.5 nM were transfected 1 day postinfection, and total RNA
was harvested 3 days after infection. HCV and g-actin RNA abundance was
measured by northern blot analysis (top). The northern blot shown represents
three independent experiments. Quantitation of HCV RNA abundance (bot-
tom). HCV RNA abundances were normalized to g-actin levels. Data from cells
transfected with control siRNAs were set to 1. Error bars represent SEM. p
values determined by Student’s t test.
(B) Model of protection of the 50 end of the HCV genome by miR-122 from
Xrn2-mediated 50-30 degradation. (a) In the presence of miR-122, Xrn2 pro-
duces few viral degradation products (thin arrow). (b) Loss of miR-122-medi-
ated protection renders the 50 triphosphate of the viral genome susceptible to
Xrn2 degradation. Helicases could remove miR-122 from the viral genome,
resulting in larger amounts of degradation products (thick arrow). (c) Removal
of the 50 triphosphate moiety of HCV RNA by a pyrophosphohydrolase could
generate 50 monophosphates that would be efficiently degraded by Xrn2 (very
thick arrow).
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presence of miR-122 or miR-124. When HCV RNAs were incu-
bated with miR-122, 50-monophosphorylated, 50-triphosphory-
lated, and 50-capped HCV RNAs were protected from degrada-
tion by Xrn2 (Figure 3B, middle). This finding shows that the
recombinant Xrn2 protein does not contain endonuclease activ-
ity. In contrast, the unrelated miR-124 failed to provide protec-
tion to 50-monophosphorylated or 50-triphosphorylated HCVCell Hosdomain I RNAs from Xrn2-mediated degradation (Figure 3B, bot-
tom). These results provide strong evidence that Xrn2 associates
with HCV RNA, and that miR-122 protects the 50 end of the viral
genome from degradation by Xrn2.
Enhancement of HCV RNA Abundance during
Sequestration of miR-122 and Concomitant
Depletion of Xrn2
MicroRNA-122, which has a 50 monophosphate, is known to
stabilize HCV RNA. To determine whether Xrn2 degrades miR-
122, Xrn2 was depleted by siRNA-mediated gene knockdown.
Figure S3A shows that Xrn2 depletion had no effect on miR-
122 abundance in both uninfected and HCV-infected cells.
These results show that, unlike mature microRNAs in C. elegans
(Chatterjee and Grosshans, 2009), human miR-122 is not
degraded by Xrn2.
Next, we investigated whether Xrn2 depletion eliminates the
miR-122 requirement for HCV RNA abundance. Briefly, control
or Xrn2 siRNAs were transfected into Huh7 cells, which were
infected with HCV 1 day later. Modified locked nucleic acids
(LNAs) with base complementarity to miR-122 or control miR-
106b (Elme´n et al., 2008; Machlin et al., 2012) were transfected
1 day after infection with HCV. RNA samples were prepared
and analyzed in northern blots (Figure 4A). As expected, samples
from cells that did not receive miR-122 LNAs, or that received
control miR-106 LNAs, showed a 4-fold increase in HCV RNA
abundance when Xrn2 was depleted (Figure 4A). Sequestration
of miR-122 by LNAs resulted in a loss of HCV RNA. However,
siRNA-mediated Xrn2 depletion restored HCV RNA abundance
by 4-fold even when miR-122 was sequestered (Figures 4A,
S3B, and S3C). One would expect that HCV RNA abundance
in siXRN2/miR-122LNA- and siNC/106LNA-treated cells should
be the same if miR-122 and Xrn2 act together. The siXRN2/
miR-122 LNA ratio is approximately 0.753 in Figures 4A and
S3B, but is 13 in Figure S3C. This variability could be explained
if not every LNA-treated, infected cell received the Xrn2 siRNA,
or if Xrn2 affects HCV RNA abundance that is independent of
miR-122. Finally, to confirm that the anti-miR-122 LNAs were
functional, the effects of miR-122-specific and control LNAs
were tested on luciferase reporter mRNAs that contain four
miR-122 seed match sites in their 30 NCRs, which are expected
to destabilize the reporter mRNA in the presence of miR-122.
Treatment with miR-122 LNAs resulted in a considerable in-
crease in luciferase activity, while addition of miR-106 LNAs
did not affect luciferase activity (Figure S3D). These findings
further argue that miR-122 protects the 50 end of the HCV RNA
genome from direct Xrn2-mediated degradation.
DISCUSSION
Our recent model on the stabilization of the HCVRNA genome by
miR-122 (Machlin et al., 2011) led us to investigate nuclease ac-
tivities fromwhich HCV RNA is being protected. Through a series
of siRNA-mediated Xrn2-depletion experiments we found that
miR-122 protected the 50 end of HCV RNA from degradation
by Xrn2. Depletion of Xrn2 caused an upregulation in HCV RNA
and protein abundance, without altering viral RNA replication
rates, but rather by increasing HCV RNA stability. This finding
presented a conundrum, because a recent report showed thatt & Microbe 16, 257–264, August 13, 2014 ª2014 Elsevier Inc. 261
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2013), while Xrn2 is known to preferentially degrade 50-mono-
phosphorylated RNAs. However, cell-free stability assays
demonstrated that RNAs containing 50 triphosphate-bearing 50
NCRs from HCV were susceptible to degradation by Xrn2.
Importantly, addition of miR-122, but not miR-124, provided
protection to 50-monophosphorylated and 50-triphosphorylated
HCV RNAs against Xrn2-mediated degradation. Ultimately,
Xrn2 depletion was able to rescue HCV RNA abundance during
miR-122 sequestration in infected cells, arguing that depletion of
Xrn2 eliminates the miR-122 requirement for viral RNA stability.
The 50-30 exoribonuclease Xrn2 has important functions in
nuclear RNA metabolism. Especially, it has crucial functions in
Pol I (El Hage et al., 2008) and Pol II transcription termination
(Kim et al., 2004; West et al., 2004). The known cellular functions
of Xrn2 are primarily linked to its exoribonuclease activity in
the nucleus, and a cytoplasmic function for this protein had not
been previously described. There is precedent that nuclear pro-
teins can have distinct functions in the cytoplasm. For example,
the nuclear poly(A) binding protein PABP2 modulates poly(A)
polymerase to polyadenylate mRNAs in the nucleus, but modu-
lates poly(A) deadenylase to shorten 30 poly(A) sequences in the
cytoplasm (Benoit et al., 2005). Thus, the different functions of
PABP2 are modulated by different interacting proteins in these
compartments (Benoit et al., 2005), as may be the case for nu-
clear and cytoplasmic Xrn2.
In our current model, extensive base-pair interactions be-
tween miR-122 and the 50 end of HCV RNA protect the integrity
of the viral genome from Xrn2-mediated degradation (Fig-
ure 4Ba). HCV RNA stability could be further regulated by RNA
helicases that could remove miR-122 and unwind secondary
structures to induce viral mRNA decay (Figure 4Bb). Such RNA
helicases could be virus-encoded proteases, such as NS3, or
host factors. For example, a recent study predicted an interac-
tion between Xrn2 and the RIG-I-like receptor, double-stranded
RNA helicase LGP2 (Li et al., 2011), suggesting that LPG2 could
be a cofactor of Xrn2. Because 50 monophosphates are the
preferred substrate for Xrn2, pyrophosphohydrolases may also
play an important role in converting the 50 triphosphate of HCV
RNA into a 50 monophopsphate for more efficient nucleolytic
degradation by Xrn2 (Figure 4Bc). For example, the pyrophos-
phohydrolase Rai1 stabilizes and enhances the exoribonuclease
activity of yeast Xrn2, Rat1 (Xiang et al., 2009). However, the hu-
man ortholog of Rai1, Dom3Z, is highly divergent and does not
appear to interact with Xrn2 (Xiang et al., 2009). Thus, exploring
the presence and action of other pyrophosphohydralases in HCV
infection would be important.
A previous study suggested that transfected type 1a HCVRNA
is degraded by both Xrn1 and the exosome complex, whereas
replicating RNA in infected cells is degraded primarily by Xrn1
(Li et al., 2013). However, miR-122 sequestration did not restore
viral RNA abundance during Xrn1 depletion (Li et al., 2013). In
contrast, Scheller et al. (Scheller et al., 2009) and Pager et al.
(Pager et al., 2013) did not find that depletion of Xrn1 significantly
affected HCV RNA abundance of type 1b and type 2 HCV geno-
type, respectively. It is thus possible that differences in cell type
or viral genotype could account for these different observations.
Xrn2 mRNA abundance increased in cells infected with the
negative-stranded respiratory syncytial virus (Ternette et al.,262 Cell Host & Microbe 16, 257–264, August 13, 2014 ª2014 Elsevi2011). We noted that treatment of cells with interferon a did
not induce Xrn2 mRNA abundance (Figure S4), indicating that
Xrn2 is not an interferon-stimulated gene. Thus, the observed
enhancement of Xrn2 steady-state protein abundance during
HCV infection may reflect stabilization of Xrn2 protein. Evidence
for this scenario comes from studies in C. elegans where Xrn2
protein is stabilized and activated by PAXT-1 (Miki et al., 2014).
Curiously, the Xrn2-interacting domain in PAXT-1 also resides
in human NKRF/NRF protein, which is involved in the transcrip-
tional repression of certain NF-kB-responsive genes and in the
constitutive silencing of the interferon-b promoter (Miki et al.,
2014). Finally, Xrn2 has been shown to be part of the type 1 inter-
feron network (Li et al., 2011), which is consistent with Xrn2 being
an antiviral effector. This antiviral effector is apparently so potent
that HCV has evolved a mechanism to evade it by subversion of
miR-122.
EXPERIMENTAL PROCEDURES
Cell Culture and Plasmid Transfections
Huh7 cells were maintained in DMEM and supplemented with 10% FBS, 1%
nonessential amino acids, and 200 mM L-glutamine. Huh7 cells were seeded
in 60 mm tissue culture plates. The following day, Huh7 cells were transfected
with 1 mg of 3XFLAG or 3XFLAG-Xrn2 plasmid using Lipofectamine 2000 (Invi-
trogen), according to the manufacturer’s protocol. LNA oligonucleotides were
delivered to cells at concentrations of 0.5, 2.5, and 25 nM using Dharmafect I
reagent (Dharmacon) according to the manufacturer’s protocol.
siRNA Transfections
The siRNA sequence for Xrn2 #1 is as follows: 50-GGAUGCAGCUGAU
GAGAAAdTdT-30. Oligonucleotides were resuspended in RNase-free water
to a 50 mM final concentration. Sense and antisense strands were combined
in annealing buffer (150 mM HEPES [pH 7.4], 500 mM potassium acetate,
10 mM magnesium acetate) to a final concentration of 20 mM, denatured for
1 min at 95C, and annealed for 1 hr at 37C. Negative-control (NC) siRNA
#3 had the following sequence: 50-AUGUAUUGGCCUGUAUUAGUU-30.
Huh7 cells were seeded in 60 mm tissue culture plates. The following day,
Huh7 cells were transfected with 2.5 nM of siRNA duplexes and Dharmafect
I reagent (Dharmacon). Twenty-four hours after transfection, cells were in-
fected with JFH-1 virus as described, and harvested 3 days after infection.
The efficiency of siRNA depletion was examined by western blot analysis.
JFH-1 Infections and Lysate Preparations
Huh7 cells were infected at 37C with the JFH-1 infectious HCV virus (Wakita
et al., 2005) at a multiplicity of infection (moi) of 0.01. Infected cells were har-
vested 3 days after. For western blot analysis, cells were washedwith PBS and
pelleted at room temperature and lysed in RIPA buffer (100 mM Tris-HCl
[pH 7.4], 150 mM NaCl, 1% sodium deoxycholic acid, 1% Triton X-100, and
0.1% SDS) containing Complete EDTA-free protease inhibitors (Roche) for
15 min on ice and pelleted for 15 min at 16,000 3 g at 4C.
Subcellular Protein Fractionation and Western Blot Analysis
Cytoplasmic and nuclear fractions were obtained by NE-PER kit (Thermo Sci-
entific) according to the manufacturer’s protocol. For western blot analysis,
30 mg cell lysate was mixed with 5 3 protein sample buffer (200 mM Tris-
HCl [pH 6.8], 50% glycerol, 25% SDS, and b-mercaptoethanol), denatured
for 5 min at 95C, and loaded onto an 8% polyacrylamide-SDS gel. After elec-
trophoresis, proteins were transferred to a PVDF membrane (Millipore) for 1 hr
at 100 V at 4C. Membranes were blocked at room temperature for 1 hr with
5% nonfat dry milk in TBS (50 mM Tris-HCl [pH 7.4] and 150 mM NaCl) with
0.1% Tween 20 (TBS/T), and then incubated overnight at 4C with primary an-
tibodies. Membranes were washed 3 3 10 min with TBS/T prior to incubating
with horseradish peroxidase-conjugated secondary antibodies diluted in 5%
milk/TBS/T for 1 hr at room temperature. After washing 3 3 10 min with
TBS/T, bound antibodies were labeled with Pierce ECL Western Blottinger Inc.
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Film (Kodak).
The following primary antibodies were used for western blot analysis: anti-
lamin A/C (N-18) (1:1,000, Santa Cruz Biotechnologies sc-6215), anti-actin
(1:1,000, Sigma A2066), anti-GAPDH (1:100,000, EMD Chemicals CB1001),
anti-HCV core (C7-50) (1:1,000, Abcam ab2740), anti-HCV NS5A (1:10,000),
and anti-Xrn2 (1:10,000, Bethyl Laboratories A301-101A). Donkey anti-
mouse-HRP (sc-2314) and donkey anti-rabbit-HRP (sc-2313) were purchased
from Santa Cruz Biotechnologies and used at 1:10,000.
Northern Blot Analysis
To visualize specific mRNAs, 10 mg TRIzol-extracted RNAwas resuspended in
loading buffer (1%MOPS-EDTA-sodium acetate [MESA], 67% formaldehyde,
and 50% formamide), denatured for 15 min at 65C, and separated in 1%
agarose/6.7% formaldehyde gels. Samples were separated in gels in MESA
buffer, containing 18% formaldehyde, at 100 V. RNA was transferred and
UV cross-linked to a Zeta probe membrane (Bio-Rad). Detection of HCV and
actin RNA (HCV [nucleotides 84–374] and g-actin (nucleotides 685–1,171)
was performed using the ExpressHyb hybridization buffer (Clontech Labora-
tories) and a-32P-dATP-RadPrime DNA-labeled probes (Invitrogen). Autora-
diographs were quantitated using ImageQuant (GE Healthcare).
Sucrose Gradient Analysis
Cells were incubated with fresh medium 4 hr prior to harvest. Cells were then
treated with 100 mg/ml cycloheximide for 3 min at 37C, followed by 23
washes with cold PBS containing 100 mg/ml cycloheximide. Lysates were pre-
pared, and gradient separation and fractionationwere performed as previously
described (Wehner et al., 2010). Fractions were incubated with 0.5 mg/ml pro-
teinase K (New England Biolabs) in the presence of 1% SDS, extracted, and
precipitated at 20C overnight. RNA was pelleted at 14,000 rpm for 15 min
at 4C and resuspended in water.
RNA Coimmunoprecipitation
Cells were lysed in polysome lysis buffer (300 mM NaCl, 15 mM Tris-HCl [pH
7.5], 15 mMMgCl, and 1% Triton X-100) with ribonucleoside vanadyl complex
(VRC, NEB S1402S) and complete protease inhibitors (Roche). Lysates were
incubated with antibodies for 1 hr at 4C with rotation. Protein A Dynabeads
were added to lysate/antibody solution and incubated at 4C for 30min. Beads
were collected by using a magnetic rack (Dynal Biotech) and washed 33 with
three volumes polysome lysis buffer. Beads were collected, and RNAs were
extracted by adding 1 ml of TRIzol to each reaction, and analyzed by northern
blotting as previously described.
Xrn2 Nuclease Activity In Vitro Assays
To generate 50 triphosphate-containing RNAs, RNA substrates were prepared
by labeling T7 IVT RNA oligonucleotides corresponding to 1–47 nucleotides of
HCV genotype 1b (HCV domain I) with 32P-pCp and T4 RNA ligase (NEB) (20 ml
of reaction; 13 T4 RNA ligase buffer [NEB], 1 mM ATP, 0.1 mg BSA, 10% [v/v]
DMSO; 100 pmol RNA, 1 mM 32P-pCp [PerkinElmer], and 10 U T4 RNA ligase)
overnight at 4C. Excess ATP and 32P-pCp was removed using a spin column
(Bio-Rad 732-6221, MicroBio Spin-6). To generate 50-monophosphorylated
RNAs, 30-end-labeled RNAs were incubated with the 50 pyrophosphohydro-
lase enzyme (NEB RppH) for 1 hr at 37C according to manufacturer’s proto-
col. 30-end-labeled RNA was capped using the ScriptCap m7G Capping
System (CELLSCRIPT C-SCCE0610) according to the manufacturer’s proto-
col. RNA was extracted with phenol/chloroform, re-extracted with chloroform,
and precipitated in 100% ethanol with 13 volume of 5M ammonium acetate
and 1 ml of 20 mg/ml glycogen (Roche). RNA was resuspended in water.
In vitro assays were carried out in Xrn2 buffer (20 mM HEPES [pH 7.5],
100 mM KCl, 4 mM MgCl2, 5% [v/v] glycerol, 1 mM DTT) with 0.766 mg of
human rXrn2 (OriGene TP323980) and 2 pmol RNA substrate in a volume
of 10 ml at 30C for 20–60 min. Reactions were quenched by addition of 3 ml
RNA loading dye (8M urea and 50mMEDTA [pH 8.0]), and samples were heat-
ed to 95C for 5 min. miR-122 or miR-124 (1 mM final) were incubated with
labeled RNAs for 10 min at 65C, then placed on ice for 10 min. Reactions
were then incubated at 30C for 20 min before addition of rXrn2. Reaction
products were then resolved on a 10% polyacrylamide/urea gel. Autoradio-
graphs were quantitated using ImageQuant (GE Healthcare).Cell HosSUPPLEMENTAL INFORMATION
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